BioSpace News Archive

This Clinical Advisory Board will work closely with NervGen as the Company prepares for its upcoming Phase 1b/2 clinical trial for spinal cord injury with its lead compound, NVG-291.

South Korea’s leading molecular diagnostics (MDx) developer Seegene Inc., (KQ 096530) is addressing the needs of small, mid-sized, and large hospitals and COVID-19 laboratories with its fully automated STARlet-AIOS: All-in-One System (AIOS).

Steven Lehrer’s 40 years of Biotech experience enhances the board of advisors with expertise in pharmaceutical, biopharmaceutical, and biosimilar R&D.

Marvel has identified a series of compounds inspired by known psychedelic molecules, that appear to be active as anti-depressants in pre-clinical testing.

CURACLE, a Korea-based biopharmaceutical company, today announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation.

Vivex Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, will be attending the Symposium on Advanced Wound Care (SAWC) in Las Vegas on October 29-31, 2021.

Today, The Association for Frontotemporal Degeneration (AFTD) released Frontotemporal Degeneration (FTD): A Voice of the Patient Report.

Oncology Pharma Inc. Pursuant to previous communications, Oncology Pharma, Inc. is making progress towards pursuing its primary goal of the Co-Development plan to bring new pharmaceutical drug formulations to market with a focused approach that aims to reduce overall costs and minimize time and duration to commercialization.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today positive preliminary results from two Phase 2 studies designed to identify the hospitalized patient population suffering from COVID-19-induced pneumonia and respiratory depression likely to respond to treatment with oral Abivertinib.